Previous close | 15,190.00 |
Open | 15,190.00 |
Bid | 15,180.00 x 0 |
Ask | 15,190.00 x 0 |
Day's range | 15,090.00 - 15,300.00 |
52-week range | 14,540.00 - 19,870.00 |
Volume | |
Avg. volume | 81,386 |
Market cap | 221.341B |
Beta (5Y monthly) | 1.12 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 50.00 (0.33%) |
Ex-dividend date | 27 Dec 2023 |
1y target est | N/A |
Onconic Therapeutics, a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for oncology and gastrointestinal disorders, announced today the results of its Phase 3 ZERO-1 study of JAQBO (zastaprazan citrate) at Digestive Disease Week (DDW) 2024, held in Washington D.C. from May 18-21, 2024.
Onconic Therapeutics, a leading biotechnology company in Korea, today announced that the Ministry of Food and Drug Safety (MFDS) of Korea has approved JAQBO (zastaprazan citrate) for the treatment of erosive gastroesophageal reflux disease (GERD) in adults.